Rankings
▼
Calendar
APLS FY 2024 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
APLS
Apellis Pharmaceuticals, Inc.
$3B
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$781M
+97.0% YoY
Gross Profit
$664M
84.9% margin
Operating Income
-$165M
-21.1% margin
Net Income
-$198M
-25.3% margin
EPS (Diluted)
$-1.60
Cash Flow
Operating Cash Flow
-$88M
Free Cash Flow
-$88M
Stock-Based Comp.
$114M
Balance Sheet
Total Assets
$885M
Total Liabilities
$657M
Stockholders' Equity
$229M
Cash & Equivalents
$411M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$781M
$397M
+97.0%
Gross Profit
$664M
$338M
+96.3%
Operating Income
-$165M
-$517M
+68.1%
Net Income
-$198M
-$529M
+62.6%
← Q4 2023
All Quarters
Q1 2024 →